Sorotan Panggilan Laba Q2 BioCryst Pharmaceuticals
· finance.yahoo.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) melaporkan hasil kuartal kedua yang ditandai oleh pertumbuhan pendapatan ORLADEYO, dimulainya pengiriman formulasi pelet-oral pediatrik, dan penyelesaian pendaftaran dalam uji coba penting navenibart untuk angioedema herediter, atau HAE. Presiden dan CEO Charlie Ga
BioCryst began shipping ORLADEYO oral pellets for pediatric patients during the week of the call. Gayer said the company had received 47 prescriptions through J...